Amid sluggish sales and dueling lawsuits, Novartis bows out of Amgen partnership, slashes staff

When Novartis and Amgen got Aimovig approved in 2018, most migraine patients relied on decades-old, mildly effective pills to ease their headaches. Proven to reduce migraines by more than 50% in hard-to-treat patients, Aimovig was expected to quickly rake in over $1 billion per year.

In the three years...

Click to view original post